Published in Obesity and Diabetes Week, February 2nd, 2004
Dharmacon will design and supply siRNA reagents for studies that will be directed by Michael Czech, PhD, professor and chair molecular medicine, UMMS, to assess several thousand gene targets over a 3-year period.
"RNAi represents a potentially valuable new approach for unraveling the mechanisms underlying diseases like diabetes and obesity that are reaching epidemic proportions," said Czech.
"We expect Dharmacon's siRNA duplexes and reagents will give us the exceptional...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.